Trial · NCT01945021
Adverse events111
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 111
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | Crizotinib 250 mg | 7 | 127 | |
| serious | Acute myocardial infarction | Cardiac disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Abdominal pain | Gastrointestinal disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Disease Progression | General disorders | Crizotinib 250 mg | 7 | 127 | |
| serious | Hepatic cyst | Hepatobiliary disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Hepatic function abnormal | Hepatobiliary disorders | Crizotinib 250 mg | 2 | 127 | |
| serious | Pneumonia | Infections and infestations | Crizotinib 250 mg | 10 | 127 | |
| serious | Appendicitis | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Bronchiolitis | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Bronchopulmonary aspergillosis | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Cellulitis | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Empyema | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Oesophageal infection | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Urinary tract infection | Infections and infestations | Crizotinib 250 mg | 1 | 127 | |
| serious | Alanine aminotransferase increased | Investigations | Crizotinib 250 mg | 2 | 127 | |
| serious | Aspartate aminotransferase increased | Investigations | Crizotinib 250 mg | 1 | 127 | |
| serious | Hepatic enzyme increased | Investigations | Crizotinib 250 mg | 1 | 127 | |
| serious | Decreased appetite | Metabolism and nutrition disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Malnutrition | Metabolism and nutrition disorders | Crizotinib 250 mg | 1 | 127 | |
| serious | Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | Crizotinib 250 mg | 1 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01945021/events?page=4